131 related articles for article (PubMed ID: 18431087)
1. Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147.
Newman JR; Gleysteen JP; Barañano CF; Bremser JR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2008 Jul; 7(7):1063-70. PubMed ID: 18431087
[TBL] [Abstract][Full Text] [Related]
2. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence.
Rosenthal EL; Kulbersh BD; Duncan RD; Zhang W; Magnuson JS; Carroll WR; Zinn K
Laryngoscope; 2006 Sep; 116(9):1636-41. PubMed ID: 16954995
[TBL] [Abstract][Full Text] [Related]
3. CD147: a potential regulator of oncogenesis non-invasive imaging of CD147 in living subjects.
Ray P; Yaghoubi SS
Cancer Biol Ther; 2008 Jul; 7(7):1071-2. PubMed ID: 18698167
[No Abstract] [Full Text] [Related]
4. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts.
Rosenthal EL; Kulbersh BD; King T; Chaudhuri TR; Zinn KR
Mol Cancer Ther; 2007 Apr; 6(4):1230-8. PubMed ID: 17431103
[TBL] [Abstract][Full Text] [Related]
5. Modulation of tumor cell growth in vivo by extracellular matrix metalloprotease inducer.
Newman JR; Bohannon IA; Zhang W; Skipper JB; Grizzle WE; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1218-24. PubMed ID: 19015455
[TBL] [Abstract][Full Text] [Related]
6. Optical imaging predicts tumor response to anti-EGFR therapy.
Helman EE; Newman JR; Dean NR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2010 Jul; 10(2):166-71. PubMed ID: 20505368
[TBL] [Abstract][Full Text] [Related]
7. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts.
Newman JR; Helman EE; Safavy S; Zhang W; Rosenthal EL
Cancer Lett; 2009 Feb; 274(2):313-8. PubMed ID: 18990485
[TBL] [Abstract][Full Text] [Related]
8. CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma.
Sweeny L; Liu Z; Bush BD; Hartman Y; Zhou T; Rosenthal EL
Exp Cell Res; 2012 Aug; 318(14):1788-98. PubMed ID: 22659167
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model.
Gleysteen JP; Newman JR; Chhieng D; Frost A; Zinn KR; Rosenthal EL
Head Neck; 2008 Jun; 30(6):782-9. PubMed ID: 18228526
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts.
Kulbersh BD; Duncan RD; Magnuson JS; Skipper JB; Zinn K; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):511-5. PubMed ID: 17520766
[TBL] [Abstract][Full Text] [Related]
11. miR-22 regulates cell invasion, migration and proliferation in vitro through inhibiting CD147 expression in tongue squamous cell carcinoma.
Qiu K; Huang Z; Huang Z; He Z; You S
Arch Oral Biol; 2016 Jun; 66():92-7. PubMed ID: 26943814
[TBL] [Abstract][Full Text] [Related]
12. A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma.
Sweeny L; Hartman YE; Zinn KR; Prudent JR; Marshall DJ; Shekhani MS; Rosenthal EL
Oral Oncol; 2013 Oct; 49(10):991-7. PubMed ID: 23920309
[TBL] [Abstract][Full Text] [Related]
13. Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts.
Withrow KP; Newman JR; Skipper JB; Gleysteen JP; Magnuson JS; Zinn K; Rosenthal EL
Technol Cancer Res Treat; 2008 Feb; 7(1):61-6. PubMed ID: 18198926
[TBL] [Abstract][Full Text] [Related]
14. Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines.
Withrow KP; Gleysteen JP; Safavy A; Skipper J; Desmond RA; Zinn K; Rosenthal EL
Otolaryngol Head Neck Surg; 2007 Nov; 137(5):729-34. PubMed ID: 17967636
[TBL] [Abstract][Full Text] [Related]
15. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.
Heath CH; Deep NL; Sweeny L; Zinn KR; Rosenthal EL
Ann Surg Oncol; 2012 Nov; 19(12):3879-87. PubMed ID: 22669455
[TBL] [Abstract][Full Text] [Related]
16.
Ma XK; Liu TL; Ren YN; Ma XP; Yao Y; Hou XG; Ding J; Wang F; Huang HF; Zhu H; Yang Z
Acta Pharmacol Sin; 2024 Feb; 45(2):436-448. PubMed ID: 37749238
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
18. CD147 promotes progression of head and neck squamous cell carcinoma via NF-kappa B signaling.
Yu B; Zhang Y; Wu K; Wang L; Jiang Y; Chen W; Yan M
J Cell Mol Med; 2019 Feb; 23(2):954-966. PubMed ID: 30421493
[TBL] [Abstract][Full Text] [Related]
19. CD147 promotes invasion and MMP-9 expression through MEK signaling and predicts poor prognosis in hypopharyngeal squamous cell carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Nanjo H; Yamada T
Adv Clin Exp Med; 2021 Jan; 30(1):41-48. PubMed ID: 33529506
[TBL] [Abstract][Full Text] [Related]
20. Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer.
Verma A; Rich LJ; Vincent-Chong VK; Seshadri M
J Oral Pathol Med; 2018 May; 47(5):484-491. PubMed ID: 29573032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
